Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

17.15 -0.30 (-1.72%)
Streaming Delayed Price Updated: 11:26 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Why Apellis Pharmaceuticals Wilted on Wednesday
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
Via Benzinga
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
Exposures Product Safety
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views
Via Benzinga
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
Via Benzinga
Earnings Scheduled For February 28, 2025
Via Benzinga
Analyst Expectations For Apellis Pharmaceuticals's Future
Via Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
Via Benzinga
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Via Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
Via Benzinga
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations. 
Via The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
The company is best known for its drug, Syfovre, a treatment for geographic atrophy. 
Via Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
Via The Motley Fool
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
Via Benzinga
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.